Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 14/20 | 0.54 |
| ▸ | RHOC | P08134 | 2/20 | 0.54 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12959500 | 0.92 | GRM3 (0.47) | RHOARHOCGRM3EPHX2CYP3A4 | |
| SCHEMBL1534248 | 0.80 | RHOA (0.64) | RHOARHOC | |
| SCHEMBL10724293 | 0.80 | GRM3 (0.68) | GRM3EPHX2 | |
| SCHEMBL1534302 | 0.79 | RHOA (0.54) | RHOARHOCCYP3A4 | |
| SCHEMBL30946669 | 0.79 | RHOA (0.62) | RHOARHOC | |
| SCHEMBL1534160 | 0.79 | RHOA (0.67) | RHOARHOC | |
| SCHEMBL10723661 | 0.78 | GRM3 (0.56) | GRM3EPHX2 | |
| SCHEMBL12449544 | 0.78 | GRM3 (0.51) | GRM3EPHX2 | |
| SCHEMBL3765179 | 0.77 | LMNA (0.63) | RHOA | |
| SCHEMBL13431504 | 0.77 | GRM3 (0.55) | GRM3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252792-A1 | METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252792-A1 | METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2011035143-A2 | METHODS AND COMPOSITIONS FOR INHIBITING RHO-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011035143-A2 | METHODS AND COMPOSITIONS FOR INHIBITING RHO-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252792-A1 | METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION | RHOA, RHOC, ROCK1 | RHOA 1/4885RHOC 2/4885GRM3 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.